Financial insights of SWKH

MyFinsight

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Total revenues	10,882	10,052	11,832	10,418
Provision (benefit) for credit losses	-931	761	-1,465	1,385
Loss on impairment of intangibles assets	209	0	NaN	NaN
Loss on disposal of inventory	314	NaN	NaN	NaN
Interest expense	1,179	1,155	1,130	1,139
Pharmaceutical manufacturing, research and development expense	147	645	758	585
Change in fair value of acquisition-related contingent consideration	0	0	NaN	NaN
Depreciation and amortization expense	2	19	19	234
General and administrative expense	3,286	2,843	3,277	2,993
Income from operations	6,676	4,629	8,113	4,082
Unrealized net (loss) gain on marketable investments	NaN	NaN	NaN	-6
Unrealized net gains on warrants	2,640	347	-424	47
Net gain on exercise and cancellation of warrants	0	0	NaN	NaN
Loss on sale of assets	0	0	-82	NaN
Discontinued operation, gain (loss) on disposal of discontinued operation, net of tax	1,601	NaN	NaN	NaN
Net loss on marketable investments	-246	37	-105	NaN
Realized gain on early payment of finance receivable	0	0	1,729	NaN
Gain (loss) on revaluation of finance receivables	0	0	-3,727	NaN
Realized and unrealized foreign currency transaction gains (losses)	25	-451	313	251
Income before income tax expense	10,696	4,562	5,817	4,374
Income tax expense	1,916	1,026	1,278	906
Net income	8,780	3,536	4,539	3,468

Basic EPS	0.72	0.29	0.37	0.28
Diluted EPS	0.72	0.29	0.37	0.28
Basic Average Shares	12,117,000	12,208,000	12,229,000	12,318,000
Diluted Average Shares	12,117,000	12,208,000	12,240,000	12,408,000

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.